Top in hem/onc: Alcohol-related cancer, FDA approval of multiple myeloma therapy
Heavy alcohol consumption contributed to a high number of cancer cases in 2020, according to data in The Lancet Oncology. However, moderate drinking contributed to nearly 1 in 7 alcohol-associated malignancies.
A report on the data was the top story in hematology/oncology last week.
Another top story was about the FDA approval of Darzalex Faspro (daratumumab and hyaluronidase-fihj, Janssen) for patients with relapsed multiple myeloma. It is the only subcutaneous anti-CD38 monoclonal antibody that is approved in combination with Pomalyst (pomalidomide, Bristol Myers Squibb) and dexamethasone.
Read these and more top stories in hematology/oncology below:
Alcohol consumption linked to 4% of global cancer cases
Alcohol consumption appeared to be linked to more than 740,000 new cancer diagnoses in 2020, equivalent to 4% of cases worldwide. Read more.
FDA approves Darzalex Faspro for use in relapsed multiple myeloma
The FDA approved daratumumab and hyaluronidase-fihj for use in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma, including those refractory to lenalidomide. Read more.
Movie ‘distraction therapy’ improves children’s experience of radiation
In the 2016 animated film “Moana,” the title character bravely battled a volcanic demon and saved her people. At University of Colorado Cancer Center, this same computer-generated princess gave a 5-year-old child with cancer the courage to face 6 weeks of radiation treatment. Read more.
Smoking exposure may predict immune checkpoint inhibitor efficacy in advanced NSCLC
Increased smoking exposure appeared associated with improved clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy, according to a study in Journal of the National Cancer Institute. Read more.
Younger cancer survivors less likely to face financial barriers to care after ACA
Financial barriers to health care decreased significantly after implementation of the Affordable Care Act among adult cancer survivors aged younger than 65 years, according to study results published in JCO Oncology Practice. Read more.